These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8995496)

  • 1. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus.
    Johnsson A; Höglund P; Grubb A; Cavallin-Ståhl E
    Cancer Chemother Pharmacol; 1996; 39(1-2):25-33. PubMed ID: 8995496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
    Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
    Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
    Najjar TA; Saad SY
    Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
    Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
    J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
    Nagai N; Ogata H
    Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer.
    Schellens JH; Planting AS; Ma J; Maliepaard M; de Vos A; de Boer Dennert M; Verweij J
    Anticancer Drugs; 2001 Sep; 12(8):667-75. PubMed ID: 11604553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study.
    Jehn CF; Boulikas T; Kourvetaris A; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(1A):471-5. PubMed ID: 17352269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in cases of esophageal cancer.
    Katano K; Tsujitani S; Maeta M; Fukuda K; Oka S; Hisamitsu K; Ikeguchi M; Kaibara N
    Oncol Rep; 2001; 8(3):605-9. PubMed ID: 11295088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
    Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
    Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic analysis of intra-peritoneal administration of cisplatin].
    Terashima M; Ikeda K; Takagane A; Sasaki N; Abe K; Araya M; Nishizuka S; Yonezawa H; Irinoda T; Nakaya T; Oyama K; Saito K
    Gan To Kagaku Ryoho; 1997 Sep; 24(12):1859-62. PubMed ID: 9382551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer.
    Sileni VC; Fosser V; Maggian P; Padula E; Beltrame M; Nicolini M; Arslan P
    Cancer Chemother Pharmacol; 1992; 30(3):221-5. PubMed ID: 1628371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
    Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
    Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
    Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
    Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck.
    Holding JD; Lindup WE; Bowdler DA; Siodlak MZ; Stell PM
    Br J Clin Pharmacol; 1991 Aug; 32(2):173-9. PubMed ID: 1931468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
    Hoebers FJ; Pluim D; Hart AA; Verheij M; Balm AJ; Fons G; Rasch CR; Schellens JH; Stalpers LJ; Bartelink H; Begg AC
    Cancer Chemother Pharmacol; 2008 May; 61(6):1075-81. PubMed ID: 17639394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.
    Hung CC; Chien CY; Chiang WF; Lin CS; Hour TC; Chen HR; Wang LF; Ko JY; Chang CH; Chen JY
    Oncotarget; 2015 Feb; 6(6):4110-25. PubMed ID: 25686830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity.
    Fukushima K; Okada A; Sasaki K; Kishimoto S; Fukushima S; Hamori M; Nishimura A; Shibata N; Shirai T; Terauchi R; Kubo T; Sugioka N
    J Pharm Sci; 2016 Jan; 105(1):324-32. PubMed ID: 26852862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Low-dose CDDP and 5-FU for head and neck cancer patients].
    Fujii M; Kanke M; Tomita T
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.